Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

H
Hägerstrand, Daniel

Karolinska Institutet
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Daniel Hägerstrand
Favorite
Häupl, Björn

Department of Medicine II, Hematology/Oncology, Goethe University Frankfurt
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Björn Häupl
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Björn Häupl
Favorite
Hüttelmaier, Stefan
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Stefan Hüttelmaier
Favorite
Hackett, Liam

Dana-Farber Cancer Institute
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Liam Hackett
Favorite
Hakobyan, Yervand

National Institute of Health MH RA, Armenia
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Yervand Hakobyan
Favorite
Hakre, Shweta

US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA
2007 - Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Shweta Hakre
Favorite
Halder, Nabanita

Department of Cancer Biology, Mayo Clinic
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Nabanita Halder
Favorite
Hallek, Michael

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Michael Hallek
Favorite
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Michael Hallek
Favorite
1056 - LYN kinase and its regulator CSK as key players in CLL-supporting macrophages
Michael Hallek
Favorite
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Michael Hallek
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Michael Hallek
Favorite
Hamilton, Audrey

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Audrey Hamilton
Favorite
Hammarlund, Ylva

Department of Medicine, Falun Hospital
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Ylva Hammarlund
Favorite
Hampel, Paul

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Paul Hampel
Favorite
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Paul Hampel
Favorite
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Paul Hampel
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Paul Hampel
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Paul Hampel
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Paul Hampel
Favorite
Han, Bing

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Bing Han
Favorite
Handunnetti, Sasanka

Princess Alexandra Hospital
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Sasanka Handunnetti
Favorite
Hanna, Benjamin

Dana-Farber Cancer Institute
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Benjamin Hanna
Favorite
Hanna, Merit

Department of Haematology, Waitemata District Health Board
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Merit Hanna
Favorite
Hansen, Gwenn
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Gwenn Hansen
Favorite
Hanson, Curtis

Mayo Clinic
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Curtis Hanson
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Curtis Hanson
Favorite
Hansson, Lotta

Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital
1125 - Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?
Lotta Hansson
Favorite
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Lotta Hansson
Favorite
Han, Weiguo

Mayo Clinic
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Weiguo Han
Favorite
Han, Yang
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Yang Han
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Yang Han
Favorite
Harrup, Rosemary

Royal Hobart Hospital, University of Tasmania
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Rosemary Harrup
Favorite
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Rosemary Harrup
Favorite
Hartley, Louise

RTI Health Solutions
1110 - Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
Louise Hartley
Favorite
Hassan, Yasmine

AstraZeneca
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Yasmine Hassan
Favorite
Hawe, Emma

RTI Health Solutions
1110 - Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
Emma Hawe
Favorite
Hay, Jodie

University of Glasgow
1022 - FOXO4 is required for the promotion of CLL growth and survival
Jodie Hay
Favorite
1027 - B cell receptor-mediated signals modulate rapid FOXO1 upregulation in chronic lymphocytic leukaemia: a role for deubiquitinate proteins?
Jodie Hay
Favorite
He, Alexander
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Alexander He
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Alexander He
Favorite
Hebart, Holger

Stauferklinikum Schwäbisch Gmünd
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Holger Hebart
Favorite
Heffernan, Clare

Wilmot Cancer Institute / University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Clare Heffernan
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Clare Heffernan
Favorite
Heimersson, Kia

Department of oncology-pathology, Karolinska Institutet
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Kia Heimersson
Favorite
Heizer, Tomas

Charles University, First Faculty of Medicine, Institute of Pathological Physiology, Center for Advanced Preclinical Imaging (CAPI)
1015 - Coupled effect of a miR-155 deficiency and hypoxia conditions leads to the upregulation of SLC2A1 (GLUT1), SLC2A3 (GLUT3) and EGLN1 genes in the leukemic B-cells
Tomas Heizer
Favorite
He, Jinghua

Janssen Scientific Affairs, LLC
2026 - Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
Jinghua He
Favorite
2027 - Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
Jinghua He
Favorite
Helbig, Daniel

Division of Hematology and Oncology, Weill Cornell Medical College
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Daniel Helbig
Favorite
He, Liye

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Liye He
Favorite
Hellerstein, Marc K.

Department of Nutritional Sciences & Toxicology, University of California at Berkeley
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Marc K. Hellerstein
Favorite
Helma, Robert

1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University
1010 - The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Robert Helma
Favorite
Heltai, Silvia

IRCCS Ospedale San Raffaele
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Silvia Heltai
Favorite
Herbaux, Charles

Hématologie Clinique, CHU Montpellier
1216 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 Rearrangement, an update from the FILO group
Charles Herbaux
Favorite
Herling, Marco

Department for Hematology, Cell Therapy and Hemostaseology, University Hospital of Leipzig
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Marco Herling
Favorite
Hermansen, Johanne

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Johanne Hermansen
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Johanne Hermansen
Favorite
Hernández, Cristina

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Cristina Hernández
Favorite
Hernández Rivas, Jesús María

University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Salamanca, Spain; Department of Hematology, University Hospital of Salamanca
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Jesús María Hernández Rivas
Favorite
Herne, Christine

Wilmot Cancer Institute / University of Rochester Medical Center
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Christine Herne
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Christine Herne
Favorite
He, Rong

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Rong He
Favorite
Hess, Lisa M

Eli Lilly and Company
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Lisa M Hess
Favorite
Heyman, Benjamin

UCSD
1115 - Venetoclax Consolidation after BTKi Based Therapy for Patients with CLL
Benjamin Heyman
Favorite
He, Zhicong

Ascentage Pharma Pty Ltd.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Zhicong He
Favorite
Hill, Brian

Cleveland Clinic
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Brian Hill
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Brian Hill
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Brian Hill
Favorite
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Brian Hill
Favorite
Hippler, Stephanie
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Stephanie Hippler
Favorite
Hjalgrim, Henrik

Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Epidemiology Research, Statens Serum Institut; Department of Clinical Medicine, Copenhagen University, Denmark.
1101 - Association between hypertension and overall survival in chronic lymphocytic leukemia
Henrik Hjalgrim
Favorite
Hlavac, Krystof

CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Krystof Hlavac
Favorite
Ho, Carrie

University of Washington
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Carrie Ho
Favorite
Hochberg, Ephraim

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Ephraim Hochberg
Favorite
Hodkinson, Brendan

Janssen
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Brendan Hodkinson
Favorite
Hoferkova, Eva

CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Eva Hoferkova
Favorite
Hofstetter, Liron
1113 - Pericardial effusion in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors
Liron Hofstetter
Favorite
Holik, Hrvoje

GH Slavonski Brod
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Hrvoje Holik
Favorite
holland, Juliette
1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Juliette holland
Favorite
Hong, Wan-Jen

Prelude Therapeutics
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Wan-Jen Hong
Favorite
Hoogeboom, Robbert

King's College London
1028 - Peripheral Blood CXCR4hiCD5hi Chronic Lymphocytic Leukaemia Cells are Primed for Returning to the Lymph Nodes for further Activation and Proliferation
Robbert Hoogeboom
Favorite
Houot, Roch

CHU Rennes
1223 - Anti-CD19 CAR T-cell therapy for patients with Richter syndrome: A LYSA Study from the DESCAR-T Registry
Roch Houot
Favorite
Hou, Wei
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Wei Hou
Favorite
Howard, Kieran

Oxford Molecular Diagnostics Centre
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Kieran Howard
Favorite
Hrochová, Kateřina

The Fingerland Department of Pathology, University Hospital Hradec Králové
1215 - Unveiling the Spectrum of Genetic Alterations in Relapsed/Refractory CLL Patients on Targeted Inhibitors: A Prospective Unicentric Study
Kateřina Hrochová
Favorite
Hrubiško, Mikuláš

Clinic of Hematology and Transfusiology, Slovak Medical University, University Hospital Bratislava
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Mikuláš Hrubiško
Favorite
Huang, Bo

Ascentage Pharma (Suzhou) Co., Ltd.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Bo Huang
Favorite
Huang, C.Chris

Bristol Myers Squibb
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
C.Chris Huang
Favorite
Huang, Ivan

Fred Hutchinson Cancer Center / UW Medicine
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Ivan Huang
Favorite
Huang, Xiaojun

Peking University Institute of Hematology
1151 - The Impact of BTK Inhibitors on COVID-19 Outcomes in Patients with Chronic Lymphocytic Leukemia: A real-world study in the Omicron wave
Xiaojun Huang
Favorite
Huang, Yanshan

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Yanshan Huang
Favorite
Huang, Ying

The Ohio State University Comprehensive Cancer Center
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Ying Huang
Favorite
Hu, Chih-Chi

Houston Methodist Research Institute
1155 - Loss of AID exacerbates the malignant progression of CLL
Chih-Chi Hu
Favorite
Huelsenbeck, Johannes

AbbVie
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Johannes Huelsenbeck
Favorite
Huntley, Kathryn

CLL Advocates Network
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Kathryn Huntley
Favorite
Hutchens, Chandra

Department of Laboratory Medicine and Pathology
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Chandra Hutchens
Favorite
Hu, Wanyi
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Wanyi Hu
Favorite
Hu, Xinting

2. Department of Hematology, Shandong Provincial Hospital, Shandong University
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Xinting Hu
Favorite
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Xinting Hu
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Xinting Hu
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Xinting Hu
Favorite
Huynh, Tiana

City of Hope - Irell and Manella Graduate School of Biological Sciences
1050 - NX-2127 and NX-5948, two clinical stage cereblon-recruiting BTK degraders, facilitate T-cell functionality in CLL
Tiana Huynh
Favorite
Huzjan Korunic, Renata

University Hospital Dubrava, School of Medicine University of Zagreb
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Renata Huzjan Korunic
Favorite
Hwang, Dobeen

Department of Immunology and Microbiology, The Scripps Research Institute
1041 - Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Dobeen Hwang
Favorite
Hwang, Steven

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Steven Hwang
Favorite